NANOLOGICA

INTERIM REPORT Q2 2026

NANOLOGICA AB (PUBL)

PERIOD IN BRIEF

FINANCIAL SUMMARY

- Net sales for the second quarter amounted to SEK 24,297 thousand (2,327) and for the half-year to SEK 45,753 thousand (13,079).
- Operating profit for the quarter amounted to SEK -18,073 thousand (-11,280) and for the half-year to SEK 48,999 thousand (-20,521). Operating profit for the first half of the year is affected by the acquisition of Syntagon being recorded as an operating income of SEK 75,676 thousand.
- Profit before tax for the quarter amounted to SEK -18,696 thousand (-12,829) and for the half-year to SEK 47,079 thousand (-23,000).
- Earnings per share before and after dilution were SEK -0.06 (-0.15) for the quarter and SEK 0.66 (-0.28) for the half-year.
- Cash and cash equivalents as of June 30 amounted to SEK 19,061 thousand (26,378)

SIGNIFICANT EVENTS DURING THE SECOND QUARTER

- In April, Nanologica received an order of appx. SEK 2 million for the company's silica-based purification media NLAB Saga® for evaluation on a production scale from a customer in India. The order was delivered during the second quarter.
- Nanologica recruited Alexandra Pichard Nielsen for the newly established role of Sales Director at Syntagon AB starting May 1. The recruitment is part of the strategy to increase focus on sales and business development with the goal of increasing Syntagon's sales.
- As a consequence of the acquisition of Syntagon, as of May 1, Group Management consists of CEO Nanologica Andreas Bhagwani, CEO Syntagon Annette Roos, and CFO Eva Osterman, with Andreas Bhagwani as Group CEO.
- Nanologica's CFO Eva Osterman has decided to leave the company with the last day of employment August 31.

SIGNIFICANT EVENTS AFTER THE END OF THE PERIOD

- Nanologica has appointed Axel Elner as new CFO. Axel Elner will take up the position on 10 November 2026.

Key Figures (group)

	2026 Apr - Jun	2025 Apr - Jun	2026 Jan - Jun	2025 Jan - Jun	2025 Jan - Dec
Net sales (TSEK)	24 297	2 327	45 753	13 079	21 127
Operating profit/loss (TSEK) *	-18 073	-11 280	48 999	-20 521	-46 801
Profit/loss before income tax (TSEK)	-18 696	-12 829	47 079	-23 000	-51 289
Cash flow from operating activities (TSEK)	-30 533	-552	-36 750	-19 746	-39 880
Cash and cash equivalents (TSEK)	19 061	26 378	19 061	26 378	3 549
Total equity (TSEK)	156 431	51 077	156 431	51 077	22 645
Average number of shares	293 970 468	88 361 010	293 970 468	80 996 019	88 369 820
Number of shares, end of period	328 769 842	88 369 820	328 769 842	88 369 820	88 369 820
Earnings per share (basic and diluted) (SEK)	-0,06	-0,15	0,66	-0,28	-0,58
Equity per share (SEK) *	0,48	0,58	0,48	0,58	0,26
Equity/asset ratio (%) *	64	46	64	46	26
Average number of employees	73	16	73	16	17
Number of employees, end of period	72	17	72	17	19

**Alternative performance measures not defined in accordance with IFRS. For definitions, see note 12.*

The quarter refers to April – June 2026. Amounts in brackets refer to comparative figures for the corresponding period last year. Unless otherwise stated, the Group is referred to in this interim report. Syntagon AB is included in the Group from January 29, 2026. Syntagon is not included in the Group's comparative figures and no comparative figures for Syntagon are reported. In this interim report, some adjustments have been made to the consolidated financial statements regarding the first quarter. The adjustments are attributable to adjustments and accounting reclassifications following the acquisition of Syntagon. Deviations from previously published information may therefore occur.

This report in English is a translation of the original report in Swedish. In case of any discrepancies, the report in Swedish takes precedence.

CONTINUED STRENGTHENED COMMERCIAL POSITION

The second quarter was characterized by continued integration of Syntagon and increased commercial activity in both of our business areas. For Syntagon, we have strengthened the sales organization through the recruitment of a new Sales Director, while Nanologica has continued to build a growing pipeline of customers who are evaluating our chromatography products.

Net sales in the second quarter of the year amounted to SEK 24.3 million, of which Syntagon accounted for SEK 22.8 million and Nanologica for SEK 2.5 million. During the quarter, Alexandra Pichard Nielsen was recruited as Sales Director for Syntagon, an important step in increasing sales and gradually improving capacity utilization and profitability.

Syntagon's position in the contract manufacturing market continues to strengthen. We see a clear trend where pharmaceutical companies increasingly want to reduce their dependence on Asian supply chains and locate more production in Europe and the US. The development is driven by increased geopolitical uncertainty, changed trade policy conditions and an increased focus on robust and secure supply chains. For Syntagon, with production in Sweden and extensive experience in pharmaceutical manufacturing, this creates interesting opportunities for new and expanded customer assignments.

During the quarter, Nanologica delivered NLAB Saga® for evaluation in production to a customer in India. Sales of chromatography products remained otherwise low, but the underlying commercial development is positive. During the first half of the year, we intensified several customer dialogues in the US and Europe, which has resulted in additional and larger customers who are now evaluating NLAB Saga® on different scales. Overall, we currently have a significant number of customers who have progressed from evaluation on a laboratory scale to a pilot scale, a subset of which are evaluating the product on a production scale. Our focus is now to gradually move these projects forward towards commercial orders. In parallel, we are working to become an approved supplier for these customers, an administrative process that is a prerequisite for future commercial deliveries. We are now an approved supplier to one customer in the US and are at the forefront of the approval processes at several others.

We therefore continue to have a positive view of the sales opportunities for our chromatography products. This is based on the fact that we now have a product quality that meets customer requirements, stable production and, above all, a significantly broader pipeline with more customers on the way to commercial use of NLAB Saga®.

The work to establish Syntagon as an independent unit within the Group is progressing according to plan and is expected to be completed during the third quarter. This will allow the organization to place an even greater focus on sales and business development.

The priorities for the second half of the year are clear: for Syntagon, it is to increase sales, capacity utilization and profitability. For Nanologica, it is to convert the growing customer pipeline into commercial orders, scale up sales and progress towards break-even.

With a strengthened sales organization, a growing customer pipeline and the integration work with Syntagon on the way to completion, we are in a good position to continue to strengthen the Group's commercial development in the second half of the year.

Södertälje in August 2026
Andreas Bhagwani, CEO

THIS IS NANOLOGICA

Better and cheaper medicines to a larger number of patients

Nanologica is a Swedish life science group that offers advanced solutions in the development, manufacture and purification of pharmaceutical substances. By combining expertise in materials science, nanotechnology, and chemical process development, with services in contract development and manufacturing, Nanologica provides an integrated platform that supports the entire value chain from early development to commercial production of pharmaceutical substances.

Nanologica's offering enables efficient and scalable production of drug substances, with particular strength within complex molecules and peptide-based drugs, such as treatments for diabetes and obesity. The company positions itself as a long-term partner to the pharmaceutical industry, with the goal of enabling more patients around the world to have access to life-saving treatments and cost-effective medicines.

The Group has about 70 employees and is headquartered in Södertälje. Nanologica's share (ticker NICA) has been listed on Nasdaq Stockholm's main market since 2022. For further information, please visit www.nanologica.com.

FINANCIAL OVERVIEW GROUP

Note that Syntagon has been consolidated in the Group's financial statements from January 29, 2026. Syntagon is not included in the Group's comparative figures and no comparative figures for Syntagon are reported.

Net sales

The Group's net sales for the second quarter amounted to SEK 24,297 thousand (2,327), of which Syntagon accounted for SEK 22,823 thousand and Nanologica for SEK 2,536 thousand. For the half-year, sales amounted to SEK 45,753 thousand (13,079), of which SEK 41,655 thousand is attributable to Syntagon and SEK 5,160 thousand to Nanologica. The increase compared to the previous year is attributable to the acquisition of Syntagon.

Results

Operating income during the quarter was positively impacted by SEK 13,479 thousand (90), mainly due to an increase in product inventory as a result of completed production of silica. Costs for raw materials and consumables increased to SEK -17,916 thousand (-275) for the quarter and to SEK -28,198 thousand (-5,908) for the half-year, which is attributable to both of the Group's business areas. Personnel costs increased to SEK -19,838 thousand (-6,177) for the quarter and SEK -34,600 thousand (-12,050) for the half-year, a result of an increased number of employees in the Group following the acquisition of Syntagon.

Operating profit for the second quarter amounted to SEK -18,073 thousand (-11,280) and for the half-year to SEK 48,999 thousand (-20,521). During the quarter, operating profit was impacted by non-recurring costs corresponding to approx. SEK 3.6 million attributable to the separation of systems and administrative processes from Syntagon's previous owners in connection with the acquisition. Operating profit for the first half of the year is affected by the fact that the acquisition of Syntagon is recorded as a non-recurring operating income in the form of negative goodwill.

Net financial items for the quarter amounted to SEK -622 thousand (-1,549) and for the half-year to SEK -1,920 thousand (-2,479). Net financial items were positively impacted by lower interest expenses as the loan of SEK 47.9 million from Flerie Invest was offset against newly issued shares and a short-term loan of SEK 15 million was repaid in April. Profit after tax for the quarter amounted to SEK – 18,696 thousand (-12,829) and for the half-year to SEK 47,079 thousand (-23,000). Earnings per share before and after dilution for the quarter were SEK -0.06 (-0.15) and for the half-year SEK 0.66 (-0.28).

Financial position

As of June 30, tangible fixed assets amounted to SEK 50,478 thousand compared to SEK 3,529 thousand at the beginning of the year. The difference is mainly made up of production equipment at Syntagon. Right-of-use assets amounted to SEK 60,682 thousand compared to SEK 7,450 thousand at the beginning of the year, where the increase is mainly attributable to leasing contracts for equipment with Syntagon.

Inventory on June 30 amounted to SEK 55,484 thousand compared to SEK 27,724 thousand at the beginning of the year, of which finished goods inventory corresponded to SEK 47,082 thousand compared to SEK 26,344 thousand at the beginning of the year. The finished goods inventory consists mainly of the silica media NLAB Saga®, but partly also of the purification media NLAB® Siv. During the quarter, finished goods inventories increased as a result of silica production.

Prepaid costs related to production amounted to SEK 23,830 thousand on the balance sheet date, compared to SEK 30,862 thousand at the beginning of the year. This mainly refers to advances to Nanologica's manufacturers for ongoing production of silica.

Cash and cash equivalents on the balance sheet date amounted to SEK 19,061 thousand, compared to SEK 3,549 thousand at the beginning of the year.

Cash flow from operating activities amounted to SEK -30,533 thousand (-552) for the second quarter and to SEK -36,750 thousand (-19,746) for the half-year. Cash flow from operating activities has been negatively impacted by an increase in inventories as a result of silica production. Total cash flow for the quarter amounted to SEK -20,130 thousand (-1,459) and for the half-year to SEK -16,166 thousand (-21,514).

Equity

The Group's reported equity at the balance sheet date amounted to SEK 156,431 thousand, compared to SEK 22,645 thousand at the beginning of the year.

Tax

As of June 30, 2026, the Group had non-capitalized tax loss carry-forwards amounting to SEK 401,097 thousand. Following the acquisition of Syntagon on January 29, 2026, group adjustments can be made from January 1, 2027. Deferred tax assets are not limited in time.



BUSINESS AREA: NANOLOGICA

Nanologica AB (publ) develops, manufactures and sells purification media for chromatography to pharmaceutical manufacturers globally. The main product NLAB Saga® is a silica-based purification media with high chemical and mechanical stability specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to its efficient and long-lasting purification, NLAB Saga® can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for peptide drugs for the treatment of diabetes and obesity.



Silica particles in a scanning electron microscope

Sales and result

Net sales for Nanologica for the second quarter amounted to SEK 2,536 thousand (2,335) and for the half-year to SEK 5,160 thousand (13,087). During the quarter, the majority of sales consisted of sales of NLAB Saga® to a peptide manufacturer in India for evaluation in production.

Operating profit for the quarter amounted to SEK -10,327 thousand (-11,280) and for the half-year to SEK -18,734 thousand (-20,521). The negative operating profit is mainly a result of low sales.

	2026 Apr - Jun		
Amount in TSEK	**Nanologica**	**Eliminations and IFRS adjustments**	**Total Group**
Net sales	2 536	-1 062	24 297
Raw materials and consumables and change in inventories, finished goods	-1 095	0	-4 437
Other operating income	167	0	778
Gross profit/loss	**1 608**	**-1 062**	**20 639**
Gross margin (gross profit / net sales)	63%	-	*85%*
Other operating items (net)	-11 935	-3 083	-38 712
Operating profit/loss	**-10 327**	**-4 145**	**-18 073**

	2026 Jan - Jun		
Amount in TSEK	**Nanologica**	**Eliminations and IFRS adjustments**	**Total Group**
Net sales	5 160	-1 062	45 754
Raw materials and consumables and change in inventories, finished goods	7 434	0	-1 471
Other operating income	309	0	2 802
Gross profit/loss	**12 903**	**74 328**	**122 475**
Gross margin (gross profit / net sales)	250%	-	*268%*
Other operating items (net)	-31 638	-3 335	-74 064
Operating profit/loss	**-18 734**	**70 993**	**48 411**

BUSINESS AREA: SYNTAGON

Syntagon is a Swedish CDMO (contract manufacturer and developer) of drug molecules. The company offers services in API development, GMP manufacturing, as well as advanced analysis and purification. The facility in Södertälje specializes in API development and API production with the capacity to take active pharmaceutical ingredients (APIs) from preclinical to clinical studies and further into commercial manufacturing.

Syntagon is part of the Group as of January 29, 2026. No comparative figures for Syntagon are reported.

Sales and result

Net sales for Syntagon amounted to SEK 22,823 thousand for the second quarter and for the half-year to SEK 41,655 thousand, of which the majority consisted of development and commercial manufacturing for existing customers. Operating profit for the quarter amounted to SEK -7,286 thousand and for the half-year to SEK -7,531 thousand. Operating profit was negatively impacted by non-recurring costs corresponding to approximately SEK 3.6 million attributable to the separation of systems and administrative processes from Syntagon's previous owners in connection with the acquisition. During the quarter, a sales director was appointed. This is expected to have a positive effect on the number of quotation requests in Q3 and increased sales in Q4.

	2026 Apr - Jun		
Amount in TSEK	**Syntagon**	**Eliminations and IFRS adjustments**	**Total Group**
Net sales	22 823	-1 062	24 297
Raw materials and consumables and change in inventories, finished goods	-3 341	0	-4 437
Other operating income	611	0	778
Gross profit/loss	**20 093**	**-1 062**	**20 639**
Gross margin (gross profit / net sales)	*88%*	-	*85%*
Other operating items (net)	-27 378	-3 083	-38 712
Operating profit/loss	**-7 286**	**-4 145**	**-18 073**

	2026 Jan - Jun		
Amount in TSEK	**Syntagon**	**Eliminations and IFRS adjustments**	**Total Group**
Net sales	41 655	-1 062	45 754
Raw materials and consumables and change in inventories, finished goods	-8 905	0	-1 471
Other operating income	2 494	0	2 802
Gross profit/loss	**35 244**	**74 328**	**122 475**
Gross margin (gross profit / net sales)	*85%*	-	*268%*
Other operating items (net)	-42 775	-3 335	-74 064
Operating profit/loss	**-7 531**	**70 993**	**48 411**

OTHER GROUP INFORMATION

Fluctuations in revenue generation

The Group generates revenues through the provision of services in contract manufacturing and contract development of drug molecules, as well as sales of products and services in chromatography. The Group's operations are seasonal. The third quarter is negatively impacted by the holiday period, particularly in the Syntagon business area, which dampens both revenue and earnings.

Employees and organization

As of 30 June 2026, the number of permanent employees was 72 (17), of which 36 (13) are women and 36 (5) are men. The number of consultants and project employees amounted to the equivalent of 6 (1.5) full-time positions.

The share and owners

Nanologica's share has been listed on Nasdaq Stockholm's main market since 2022, under the ticker NICA. The ISIN code is SE0005454873. As of June 30, the number of registered shares in the company amounted to 328,769,842 and the registered share capital to SEK 6,575,396.84. The share's quota value is SEK 0.051 per share.

Ownership structure as of 30 June 2026

A list of owners is also published on the company's website.

Owners as of 30 June 2026	Number of shares	Share %
Flerie Invest AB	163 358 321	49,7
Ardena Sweden AB	21 453 780	6,5
Academy of Fine Arts	13 194 060	4,0
Vega Bianca AB	11 534 528	3,5
Avanza Pension	6 678 532	2,0
Clearstream Banking S.A.	5 532 150	1,7
CJ Hall Invest AB	4 084 746	1,2
Nordnet Pensionsförsäkring AB	3 807 089	1,2
SEB AB Luxembourg Branch	2 984 182	0,9
Peter Olaisson	1 920 301	0,6
The ten largest shareholders	**234 547 689**	**71,3**
Other shareholders (4,220)	**94 222 153**	**28,7**
Total	**328 769 842**	**100,0**

Share-based incentive programs

Warrant program 2023/2026 for management team and employees

The program was resolved by the AGM 2023. Each warrant of series TO 2023/2026 entitles the holder to subscribe for one new share in the company during the period 1 August 2026 to 30 November 2026 at a subscription price of SEK 30 per share. In the program, 180,000 of the total 245,000 options have been subscribed for. Based on the number of shares in the company as of the date of the report, the dilution effect will be negligible if all options under the program are exercised. The program does not entail any cost to the company.

Financial calendar

Interim Report Q3 2026	26 November 2026
Year-End Report 2026	18 February 2027
Annual Report 2026	23 April 2027

Financial reports will be published on Nanologica's website at 08.10 a.m. CET on the specified date.

Annual General Meeting 2026

Nanologica's Annual General Meeting 2026 was held on 21 May, at which the following resolutions were passed, among other things:

- Adoption of the income statement and balance sheet, allocation of profit, and discharge from liability for the members of the Board of Directors and the CEO for the financial year 2025.
- Re-election of the Board members Thomas Eldered, Gisela Sitbon, Mattias Bengtsson, Lena Torlegård and Jeremie Trochu, and new election of Mark Quick and Erik Haeffler for the period until the next Annual General Meeting. Thomas Eldered was elected Chairman of the Board. Board member Anders Rabbe had declined re-election.
- Amendment of the Articles of Association so that the share capital shall amount to a minimum of SEK 5,500,000 and a maximum of SEK 22,000,000, and a resolution to reduce the company's share capital by SEK 10,191,865.102, without cancellation of shares, to cover losses.

- To authorize the Board of Directors to resolve issues of shares, warrants and/or convertibles in accordance with the Board's proposal.

Minutes from the Annual General Meeting are available on the company's website.

Future prospects

This report contains forward-looking statements. Actual outcomes may differ from those statements. Internal and external factors may affect the Group's results.

Since 2018, significant investments have been made in a modern equipment park at Syntagon, which has laid the foundation for the company to grow profitably in the future. With an increased focus on sales and business development, primarily through a strengthened sales organization, the business is expected to have good opportunities to grow.

Nanologica's large-scale production of silica is now stable, which means that larger product volumes can be delivered to customers with well-defined and market-based delivery times. This is expected to significantly facilitate the commercialization of NLAB Saga®. The company's opportunities to initiate significantly higher sales of silica media for chromatography with continued sales growth in the coming years are therefore considered to be good.

Risks and uncertainties

The Group makes assumptions, assessments and estimates that affect the content of the financial statements. Actual results may differ from these estimates and estimates, as is also reflected in the accounting policies. The objective of the Group's risk management is to identify, prevent, measure, control and mitigate risks in the business.

The risks in the Group's operations include strategic risks related to, among other things, the Group companies' operations, industry, legal and regulatory risks, financing of scale-up projects, commercialization, research, trademarks and external requirements, as well as operational risks such as production risks and price changes of raw materials and inputs, as well as currency fluctuations. A detailed description of risk exposure and risk management can be found in Nanologica's Annual Report for 2025 on pages 51–54. No significant changes to material risks or uncertainties have occurred during the reporting period other than those described under the section "External factors".

period other than those described under the section "External factors".

External factors

The geopolitical situation as well as the trade tensions between the United States and other countries did not have any direct impact on the Group's operations during the quarter. However, there is a risk that the supply of raw materials and consumables may become negatively affected as well as that prices of raw materials may rise.

As sales and purchases are made in different currencies, exchange rates may affect the Group's earnings. Regarding fluctuations in exchange rates, the Group's manufacturing and commitments are mainly in British pounds and sales mainly in euros and US dollars. The Group has not hedged any exchange rates at present.

The company works continuously to identify, evaluate and manage external factors that have an impact on the operational activities.

Auditors' review

This interim report has not been reviewed by the company's auditors.

ASSURANCE

The Board of Directors and the CEO assure that this interim report provides a fair overview of the Group's operations, position and results and describes significant risks and uncertainties faced by the Group's companies.

31 August 2026

Thomas Eldered *Chairman of the board*	Mattias Bengtsson *Board member*	Erik Haeffler *Board member*
Mark Quick *Board member*	Gisela Sitbon *Board member*	Lena Torlegård *Board member*
Jeremie Trochu *Board member*	Andreas Bhagwani *Chief Executive Officer*	

For further information, please contact:

CEO Andreas Bhagwani andreas.bhagwani@nanologica.com

CFO Eva Osterman eva.osterman@nanologica.com

NANOLOGICA

FINANCIAL REPORTS AND NOTES

CONSOLIDATED INCOME STATEMENT

Amounts in TSEK	2026 Apr- Jun	2025 Apr - Jun	2026 Jan - Jun	2025 Jan - Jun	2025 Jan- Dec
Net sales	24 297	2 327	45 753	13 079	21 127
Change in inventories, finished goods	13 479	90	18 857	-3 858	-916
Other operating income	1 082	-175	6 590	-101	-77
Negative goodwill acquisition	-304	0	75 676	0	0
Operating expenses					
Raw materials and consumables	-17 916	-275	-28 198	-5 908	-15 915
Other external costs	-11 230	-3 522	-20 796	-6 949	-16 706
Staff costs	-19 838	-6 177	-34 600	-12 050	-24 549
Depreciation and impairment of tangible, intangible and right-of-use assets	-7 056	-3 697	-12 661	-7 339	-12 442
Valutaion of other current assets	0	0	0	2 409	2 409
Other operating expenses	-588	148	-1 622	197	267
Total operating expenses	-56 628	-13 522	-97 877	-29 641	-66 937
Operating profit/loss	**-18 073**	**-11 280**	**48 999**	**-20 521**	**-46 801**
Financial items					
Financial income	62	0	187	124	217
Financial costs	-684	-1 549	-2 107	-2 603	-4 704
Total financial items	-622	-1 549	-1 920	-2 479	-4 487
Profit/loss before income tax	**-18 696**	**-12 829**	**47 079**	**-23 000**	**-51 289**
Income tax	0	0	0	0	0
Profit/loss for the period attributable to owners of parent company	**-18 696**	**-12 829**	**47 079**	**-23 000**	**-51 289**
Other comprehensive income	0	0	0	0	0
Total comprehensive profit/loss for the period attributable to owners of parent company	**-18 696**	**-12 829**	**47 079**	**-23 000**	**-51 289**
Earnings per share (basic and diluted), SEK	-0,06	-0,15	0,66	-0,28	-0,58
Average number of ordinary shares during the period	293 970 468	88 361 010	293 970 468	80 996 019	88 369 820
Ordinary shares outstanding at the closing date	328 769 842	88 369 820	328 769 842	88 363 527	88 369 820

CONSOLIDATED BALANCE SHEET

Amounts in TSEK	2026 Jun 30	2025 Jun 30	2025 Dec 31
ASSETS			
Fixed assets			
Intangible fixed assets			
Capitalized expenditure for research and development and similar	7 376	11 801	9 464
Tangible fixed assets	50 478	2 892	3 529
Right-of-use assets	60 682	8 021	7 450
Total fixed assets	**118 535**	**22 714**	**20 443**
Current assets			
Inventories	55 484	28 688	27 724
Accounts receivable	19 127	347	3 814
Tax assets	51	0	0
Other receivables	4 367	292	875
Prepaid expenses and accrued income	26 966	33 672	31 707
Cash and cash equivalents	19 061	26 378	3 549
Total current assets	**125 057**	**89 377**	**67 668**
TOTAL ASSETS	**243 592**	**112 091**	**88 111**
EQUITY AND LIABILITIES			
Equity			
Share capital including ongoing issues	6 575	4 507	4 507
Additional paid-in capital	519 361	442 115	442 053
Profit/loss brought forward from actual period	-369 506	-395 544	-423 915
Total equity attributable to parent company shareholders	156 431	**51 077**	**22 645**
TOTAL EQUITY	**156 431**	**51 077**	**22 645**
Long-term liabilities			
Lease liabilities	43 198	257	208
Other long-term liabilities	0	42 875	28 583
Total long-term liabilities	**43 198**	**43 132**	**28 791**
Current liabilities			
Accounts payable	15 853	5 643	6 883
Lease liabilities	10 434	1 479	1 967
Current loan liabilities	0	4 991	19 292
Other liabilities	2 496	1 024	692
Accrued expenses and deferred income	15 181	4 744	7 842
Total current liabilities	**43 963**	**17 882**	**36 676**
Total liabilities	87 161	**61 014**	**65 467**
TOTAL EQUITY AND LIABILITIES	**243 592**	**112 091**	**88 111**

STATEMENT ON CHANGES IN EQUITY FOR THE GROUP

Amounts in TSEK	2026 Apr-Jun	2025 Apr - Jun	2026 Jan - Jun	2025 Jan - Jun	2025 Jan - Dec
Total equity at the beginning of the period	**98 106**	**63 940**	**22 645**	**74 112**	**74 112**
Profit/loss for the period	-18 696	-12 829	47 079	-23 000	-51 289
Total comprehensive income for the period	**-18 696**	**-12 829**	**47 079**	**-23 000**	**-51 289**
Share capital	-10 192	0	-10 192	0	0
Profit carried forward	4 292	0	4 316	0	0
Rights issue	83 205	38	95 847	38	38
Transaction costs	0	-95	-6 278	-95	-157
Aquisition costs	-304	0	2 996	0	0
Group adjustments	20	24	16	24	-58
Total transactions with shareholders	**77 021**	**-34**	**86 706**	**-34**	**-177**
					0
Total equity at the end of the period	**156 431**	**51 077**	**156 431**	**51 077**	**22 645**

CONSOLIDATED CASH FLOW STATEMENT

Amounts in TSEK	2026 Apr - Jun	2025 Apr - Jun	2026 Jan - Jun	2025 Jan - Jun	2025 Jan - Dec
Operating activities					
Operating profit/loss	-18 073	-11 280	48 411	-20 521	-46 801
Adjustment for items not affecting cash flow	7 360	3 608	-62 427	7 251	12 264
Valuation of other current assets	0	0	0	-2 409	-2 409
Interest received	13	-19	54	104	197
Interest paid	-41	-1 018	-1 118	-2 046	-3 979
Income taxes received/paid	-15	0	-22	0	0
Cash flow from operating activities before changes in working capital	**-10 756**	**-8 709**	**-15 103**	**-17 620**	**-40 728**
Cash flow from changes in working capital					
Increase (-) / decrease (+) of inventories	-14 002	-54	-19 072	4 056	5 021
Increase (-) / decrease (+) of operating receivables	3 957	7 804	-5 873	390	-1 607
Increase (+) / decrease (-) of operating liabilities	-9 732	407	3 297	-6 572	-2 567
Cash flow from operating activities	**-30 533**	**-552**	**-36 750**	**-19 746**	**-39 880**
Investing activities					
Investments in intangible assets	0	0	-28	0	0
Investments in tangible fixed assets	-464	0	-464	0	-999
Losses when liquidating subsidiary	0	0	0	0	-83
Auqisition of subsidiary	-304	0	-3 788	0	0
Cash flow from investing activities	**-768**	**0**	**-4 280**	**-55 121**	**-1 082**
Financing activities					
Rights issue for the year	83 205	38	87 265	38	38
Transaction costs	0	-95	-2 978	-95	-157
New loans	0	0	15 000	0	0
Amortization of lease liabilities	-3 259	-889	-5 648	-1 750	-3 143
Amortization of financial loans	-62 875	39	-62 875	39	48
Repayment of shareholder contributions	-5 900	0	-5 900	0	0
Cash flow from financing activities	**11 171**	**-907**	**24 864**	**-1 768**	**-3 213**
Total cash flow for actual period	**-20 130**	**-1 459**	**-16 166**	**-76 635**	**-44 175**
Cash and cash equivalents, opening balance	39 253	28 349	35 172	48 430	48 430
Exchange rate difference in cash and cash equivalents	-61	-512	55	-538	-706
Cash and cash equivalents, closing balance	**19 061**	**26 378**	**19 061**	**-28 743**	**3 549**

NOTES

NOTE 1 GENERAL INFORMATION

This report covers the Swedish parent company Nanologica AB (publ), corporate identity number 556664–5023 and its subsidiaries. The parent company is a limited liability company with its registered office in Stockholm, Sweden. The address of the head office is Tallvägen 6, 151 38 Södertälje, Sweden. The Group's main business is the provision of services in contract manufacturing and contract development of drug molecules, as well as the production and sale of chromatography products.

Nanologica AB has six subsidiaries; Syntagon AB, Syntagon Denmark ApS, Nanghavi AB, Nanologica Black AB, Nanologica Yellow AB and Nlab Bioscience S.A. Nlab Bioscience S.A is being wound up. Nanghavi AB, Nanologica Black AB and Nanologica Yellow AB are dormant at the time of publication of the report.

The interim report for Q2 2026 has been approved for publication on 31 August 2026 in accordance with the Board of Directors' decision on 31 August 2026.

NOTE 2 ACCOUNTING PRINCIPLES

The consolidated financial statements for Nanologica AB have been prepared in accordance with International Financial Reporting Standards (IFRS) as adopted by the EU, the Annual Accounts Act (ÅRL) and the Swedish Financial Reporting Council RFR 1 Supplementary Accounting Rules for Groups. The Parent Company's financial reports have been prepared in accordance with the Annual Accounts Act and RFR 2 Accounting for Legal Entities.

The interim report has been prepared in accordance with IAS 34 Interim Financial Reporting and the Annual Accounts Act. Disclosures in accordance with IAS 34 are disclosed both in notes and elsewhere in the interim report. The accounting policies and calculation methods applied are in accordance with those described in the 2025 Annual Report. ESMA's (European Securities and Markets Authority) guidelines on alternative performance measures are applied and this entails disclosure requirements regarding financial measures that are not defined in accordance with IFRS. For key performance measures not defined in accordance with IFRS, see Note 12 Definition of key performance measures.

The quarter refers to the first quarter of 2026 unless otherwise stated. Amounts expressed in SEK thousand and SEK million refer to thousands of Swedish kronor and millions of Swedish kronor respectively. Amounts in brackets refer to comparative figures for the previous year.

NOTE 3 SIGNIFICANT ACCOUNTING ASSESSMENTS AND ASSUMPTIONS

Important estimates and assessments are described in detail in Nanologica's Annual Report 2025 on pages 74–76. No significant changes in estimates and estimates have been noted for the reporting period. This report includes statements that are forward-looking and actual results may differ from those stated.

NOTE 4 SEGMENTS

An operating segment is a part of a group that conducts business from which it can generate revenue and incur costs, and for which stand-alone financial information is available. The Group's breakdown by operating segment is consistent with the internal reports used by the Group's top executive decision-makers to monitor operations and allocate resources across business segments. The CEO is the Group's highest executive decision-maker. In Nanologica, it is therefore the reports that the CEO receives on the results in different parts of the Group that form the basis for the segment information. For more information about the Group's operating segments, please refer to pages 9-10 in the interim report.

NOTE 5 DISTRIBUTION OF INCOME

The Group's distribution of revenues broken down by revenue type, geographic market, and major customers. All sales of goods have taken place at a certain time. The provision of services has been recognized as revenue over time when the services have been performed.

Composition of net sales, per product type (TSEK)	2026 Apr-Jun	2025 Apr - Jun	2026 Jan - Jun	2025 Jan - Jun	2025 Jan - Dec
Silica for preparative chromatography	2 035	1 844	4 627	11 948	18 141
Columns for analytical chromatography	501	483	533	1 131	1 447
Application development and similar services	18 589	0	18 589	0	0
Other chromatography media	0	0	0	0	1 539
Contract Development and Manufacturing Services	0	0	17 521	0	0
Invoiced Costs	3 172	0	4 483	0	0
Total	**24 297**	**2 327**	**45 753**	**13 079**	**21 127**

Composition of net sales, per region (TSEK)	2026 Apr-Jun	2025 Apr - Jun	2026 Jan - Jun	2025 Jan - Jun	2025 Jan - Dec
Sweden	0	0	5 819	0	0
China	0	2 257	8	12 310	18 283
India	2 035	71	2 044	122	182
USA	2 074	0	14 640	0	1 524
Europe	17 917	0	20 971	27	77
Rest of the World	2 271	0	2 271	620	1 062
Total	**24 297**	**2 327**	**45 753**	**13 079**	**21 127**

NOTE 6 INVENTORIES

Amounts in TSEK	2026 Jun 30	2025 Jun 30	2025 Dec 31
Raw materials	5 260	131	0
Semi-finished products and production in progress	3 142	5 998	1 380
Finished products	47 082	22 560	26 344
Total	**55 484**	**28 688**	**27 724**

NOT 7 INFORMATION ON FINANCIAL ASSETS AND LIABILITIES

For assets and liabilities that are reported at amortized cost, the company assesses that the carrying value of its receivables and liabilities corresponds to fair value. This assessment is based, inter alia, on the discount effect, which is considered to be insignificant in view of the maturity of the claims and liabilities and the prevailing market conditions. Since the company's receivables and liabilities mainly have a short maturity, the difference between carrying amount and fair value is considered to be negligible.

NOTE 8 ADJUSTMENTS FOR ITEMS NOT AFFECTING CASH FLOW

Amounts in TSEK, group	2026 Apr - Jun	2025 Apr - Jun	2026 Jan - Jun	2025 Jan - Jun	2025 Jan - Dec
Depreciations	7 056	3 608	12 660	7 250	12 354
Write-downs/disposals of fixed assets	0	0	0	0	-90
Negativ goodwill acquisition	-303	0	-75 695	0	0
Total	**6 753**	**3 608**	**-63 034**	**7 251**	**12 264**

Amounts in TSEK, parent company	2026 Apr - Jun	2025 Apr - Jun	2026 Jan - Jun	2025 Jan - Jun	2025 Jan - Dec
Depreciations	1 218	2 375	2 534	5 226	8 014
Write-downs/disposals of fixed assets	0	0	0	0	-90
Write-downs/disposals of other assets	0	-89	0	-89	-89
Total	**1 218**	**2 286**	**2 534**	**5 137**	**7 835**

NOTE 9 RELATED PARTY TRANSACTIONS

Transactions with Flerie Invest AB regarding loans. Flerie Invest AB is Nanologica's largest shareholder. Thomas Eldered is the main owner and chairman of the board of Flerie Invest AB, as well as a board member of Nanologica AB.

Information about loans

Loans from Flerie Invest AB were raised on market terms during the first half of 2022. The annual interest rate on the loans is 8 per cent and interest on the loans has been paid quarterly. During the second quarter, the remainder of the loan was offset against shares, after which the loan on the balance sheet date amounted to SEK 0.

Transactions during the second quarter

Set-off of outstanding loan amount of SEK 47,875 thousand against shares.

NOTE 10 ACQUISITION ANALYSIS

On January 29, Nanologica AB (publ) acquired 100% of the shares in Ardena Södertälje AB from Ardena Sweden AB. The purchase price amounted to SEK 8.6 million, which was paid with newly issued shares in Nanologica AB (publ) and a cash consideration of EUR 1. The equity instrument has been measured at fair value on the acquisition date in accordance with IFRS3.

The fair value of identifiable net assets amounted to SEK 87.5 million. The purchase price was less than the fair value of the assets by SEK 75.2 million. Following a reassessment of assets, liabilities and purchase price in accordance with IFRS 3.36, the difference has been recognized as gain on preferential business combinations in the income statement.

The purpose of the acquisition is to strengthen Nanologica's capacity and expertise in production and to accelerate the company's growth. From 2026, the acquisition is expected to contribute positively to the Group's earnings and cash flow and create meaningful operational and commercial synergies.

Acquisition analysis (TSEK)	
Intangible fixed assets	50 883
Deferred tax assets	29
Inventories	8 689
Accounts receivable	10 009
Prepaid expenses and accrued income	3 550
Cash and cash equivalents	31 624
Total assets	**104 783**
Accounts payable	-6 489
Other current liabilities	-1 339
Accrued expenses and deferred income	-9 477
Total liabilities	**-17 305**
Total	**87 478**
Latent tax debt	-21
Deducted	
Purchase price, not affecting cash flow	-8 582
Acquistion costs	-3 688
Acquistion value	**75 187**

NOTE 11 EVENTS AFTER THE END OF THE QUARTER

- Nanologica has appointed Axel Elner as its new CFO. Axel Elner will take up the position on 10 November 2026.

NOTE 12 DEFINITIONS OF KEY FIGURES

The company presents certain financial measures that are not defined in accordance with IFRS. These alternative performance measures are used in internal reporting and as part of management's follow-up of the Group's results and financial position. The company believes that these measures provide valuable supplementary information to investors and the company's management as they enable evaluation and benchmarking of the company's performance. Because not all companies calculate financial measures in the same way, they are not always comparable to measures used by other companies. Therefore, these financial measures should not be regarded as a substitute for measures defined under IFRS Reported key performance measures are defined in accordance with IFRS unless otherwise stated. ESMA's guidelines on *alternative performance measures* apply, which means disclosure requirements for financial measures that are not defined according to IFRS.

Definitions of alternative performance measures

Operating profit (EBIT)

Profit before net financial items and income tax. (Earnings before interest and taxes).

Operating margin, %

Operating profit in relation to sales. In cases where the margin is negative, the margin is not reported, but only the term "neg".

Earnings before depreciation and amortization (EBITDA)

The multi-year review reports the EBITDA (*Earnings Before Interest, Taxes, Depreciation and Amortization*) performance measure. EBITDA is calculated as operating profit with the reversal of depreciation and amortization of property, plant and equipment, intangible fixed assets and right-of-use assets.

Equity per share

Equity divided by the outstanding number of shares at the end of the period.

Cash flow from operating activities per share

Cash flow from operating activities in relation to the average number of shares before dilution.

Equity ratio

Equity in relation to the balance sheet total.

Average number of shares during the period

Calculated as an average of the number of ordinary shares outstanding during the reporting period on a daily basis.

** Derivation of alternative performance measures*

	2026 Apr-Jun	2025 Apr - Jun	2026 Jan - Jun	2025 Jan - Jun	2025 Jan - Dec
A. Operating profit/loss (TSEK)	-18 073	-11 280	48 999	-20 521	-46 801
B. Net sales (TSEK)	24 297	2 327	45 753	13 079	21 127
A/B = Operating profit/loss (%)	**neg**	**neg**	**1,07**	**neg**	**neg**
A. Operating profit/loss (TSEK)	-18 073	-11 280	48 999	-20 521	-46 801
B. Depreciation and amortization of tangible, intangible and right-of-use assets (TSEK)	-7 056	-3 697	-12 661	-7 339	-12 442
A-B = Earnings before interest, taxes, depreciation and amortization (EBITDA), (TSEK)	**-11 017**	**-7 583**	**61 660**	**-13 181**	**-34 359**
A. Cashflow from operating activities (TSEK)	-30 533	-552	-36 750	-19 746	-39 880
B. Average number of shares before dilution during the period*	293 970 468	88 361 010	293 970 468	80 996 019	88 369 820
A/B*1 000 = Cashflow from operating activities per share (SEK)	**-0,10**	**-0,01**	**-0,13**	**-0,24**	**-0,45**

	2026 Jun 30	2025 Jun 30	2025 Jan - Dec
A. Equity according to the balance sheet (TSEK)	156 431	51 077	74 112
B. Total assets according to balance sheet (TSEK)	243 592	112 091	154 513
A/B = Equity/assets ratio (%)	**64**	**46**	**48**
A. Equity according to the balance sheet (TSEK)	156 431	51 077	74 112
B. Number of shares before and after dilution*	328 769 842	88 369 820	88 369 820
A/B*1000 = Equity per share (SEK)	**0,48**	**0,58**	**0,84**

** In the event of a negative result, no recalculation is made for dilution.*

GROUP QUARTERLY DATA

Amounts in TSEK unless otherwise stated	2026-Q2	2026-Q1	2025-Q4	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3
Statement of comprehensive income								
Net sales	24 297	21 456	5 205	2 843	2 327	10 751	6 715	611
Total operating expenses	-56 628	-41 249	-17 981	-19 315	-13 522	-16 118	-24 541	-20 656
Operating profit before depreciation and amortization (EBITDA)*	-11 017	72 677	-13 206	-7 972	-7 583	-5 598	-8 236	-17 037
Operating profit/loss (EBIT)*	-18 073	67 073	-15 706	-10 575	-11 280	-9 241	-11 890	-22 203
Operating margin,%*	-18 696	3,1	neg	neg	neg	neg	neg	neg
Total financial investments	neg	-1 298	-1 027	-981	-1 549	-930	-2 144	-1 499
Profit/loss before income tax	-622	65 775	-16 733	-11 556	-12 829	-10 171	-14 033	-23 701
Total comprehensive profit/loss for the period attributable to owners of parent company	-18 696	65 775	-16 733	-11 556	-12 829	-10 171	-14 033	-23 701
Consolidated financial position								
Total fixed assets	118 535	124 924	20 443	20 422	22 714	25 991	29 633	33 287
Total current assets	105 996	97 022	64 120	65 784	63 000	70 748	65 036	57 745
Cash and cash equivalents	19 061	39 253	3 549	13 970	26 378	28 348	48 430	4 087
Total equity	156 431	97 518	22 645	39 378	51 077	63 940	74 112	-8 838
Total long-term liabilities	43 198	45 355	28 791	28 834	43 132	42 899	282	1 140
Total current liabilities	43 963	118 327	36 676	31 964	17 882	18 248	68 705	102 817
Consolidated statement of cash flow								
Cash flow from operating activities	-30 533	-6 217	-9 452	-10 682	-552	-19 194	-24 595	-23 474
Cash flow from investing activities	-768	-3 512	-210	-872	0	0	0	-45
Cash flow from financing activities	11 171	13 694	-649	-796	-907	-862	68 893	12 742
Total cash flow for actual period	-20 130	3 965	-10 311	-12 350	-1 459	-20 056	44 297	-10 776
Other Key Figures								
Equity/assets ratio, %*	64	37	26	39	46	51	52	-9
Number of employees at the end of the period	72	72	19	19	18	16	16	16
Average number of employees during the period	73	71	19	18	16	16	15	15
Average number of employees and consultants during the period	79	75	21	20	18	19	19	19
Data per share								
Earnings per share before and after dilution, SEK	-0,06	0,73	-0,19	-0,13	-0,15	-0,14	-0,19	-0,54
Equity per share (before dilution), SEK*	0,48	0,81	0,26	0,45	0,58	0,72	0,84	-0,20
Cash flow from operating activities per share, SEK*	-0,10	-0,07	-0,11	-0,12	-0,01	-0,26	-0,33	-0,53
Share price at the end of the period, SEK	0,39	0,39	0,78	1,15	1,16	1,30	1,82	2,24
Number of shares before dilution on average during the period	293 970 468	90 629 957	88 369 820	88 369 820	88 361 010	73 631 029	73 631 029	44 178 618
Number of shares before dilution at the end of the period	328 769 842	119 973 600	88 369 820	88 369 820	88 369 820	88 357 234	88 357 234	44 178 618
Number of warrants at the end of the period	180 000	180 000	180 000	180 000	180 000	180 000	180 000	180 000

** Alternative performance measures not defined in accordance with IFRS. For definitions, see note 12.*

INCOME STATEMENT FOR THE PARENT COMPANY

Amounts in TSEK	2026 Apr-Jun	2025 Apr - Jun	2026 Jan - Jun	2025 Jan - Jun	2025 Jan - Dec
Net sales	2 536	2 327	5 160	13 079	21 127
Change in inventories, finished goods	13 479	90	22 010	-3 858	-916
Other operating income	167	-175	309	-101	-77
Operating expenses					
Raw materials and consumables	-14 575	-275	-22 445	-5 908	-15 915
Other external costs	-4 084	-4 470	-8 491	-8 835	-20 057
Staff costs	-6 529	-6 177	-12 520	-12 050	-24 549
Depreciation and amortization of tangible, intangible and right-of-use assets	-1 218	-2 375	-2 534	-5 225	-8 014
Valuation of other current assets	0	0	0	2 409	2 409
Other operating expenses	-104	142	-222	191	237
Total operating expenses	-26 510	-13 155	-46 213	-29 419	-65 890
			0	0	
Operating profit/loss	**-10 327**	**-10 913**	**-18 734**	**-20 299**	**-45 755**
Financial items					
Profit/loss from group companies	0	0	5 000	0	0
Exchange rate differences	-61	-512	55	-538	-706
Interest income and similar profit/loss items	13	0	23	124	217
Interest expense and similar profit/loss items	-41	-1 016	-1 118	-2 012	-3 937
Profit/loss from financial items	-88	-1 528	3 959	-2 426	-4 426
Profit/loss before income tax	**-10 415**	**-12 441**	**-14 775**	**-22 725**	**-50 181**
Income tax	0	0	0	0	
Profit/loss for the period	**-10 415**	**-12 441**	**-14 775**	**-22 725**	**-50 181**

STATEMENT OF COMPREHENSIVE INCOME FOR THE PARENT COMPANY

Amounts in TSEK	2026 Apr-Jun	2025 Apr - Jun	2026 Jan - Jun	2025 Jan - Jun	2025 Jan - Dec
Profit/loss for the period	-10415	-12 441	-14 775	-22 725	-50 181
Other comprehensive income					
Items that may be reclassified to result for the year	0	0	0	0	0
Comprehensive income for the period	**-10 415**	**-12 441**	**-14 775**	**-22 725**	**-50 181**

BALANCE SHEET FOR THE PARENT COMPANY

Amounts in TSEK	2026 Jun 30	2025 Jun 30	2025 Dec 31
ASSETS			
Fixed assets			
Intangible assets			
Capitalized expenditure for research and development and similar	7 376	11 801	9 464
Total intangible assets	7 376	11 801	9 464
Tangible assets			
Equipment, tools and installations	3 083	2 892	3 529
Financial assets			
Participations in group companies	12 469	100	100
Total fixed assets	**22 928**	**14 793**	**13 093**
Current assets			
Inventories			
Inventories	49 414	28 688	27 724
Current receivables			
Accounts receivable	3 357	347	3 814
Other receivables	821	292	875
Prepaid expenses and accrued income	26 542	34 815	32 674
Total current receivables	30 720	35 455	37 363
Cash and cash equivalents			
Cash and cash equivalents	6 952	26 201	3 454
Total current assets	**87 086**	**90 344**	**68 541**
TOTAL ASSETS	**110 014**	**105 136**	**81 634**

BALANCE SHEET FOR THE PARENT COMPANY

Amounts in TSEK	**2026 Jun 30**	**2025 Jun 30**	**2025 Dec 31**
EQUITY AND LIABILITIES			
Equity			
Share capital	6 575	4 507	4 507
Fund for development expenditure	1	120	19
Total restricted equity	6 576	4 627	4 526
Non-restricted equity			
Share premium reserve	519 361	442 115	442 053
Profit/loss brought forward	-414 423	-378 157	-378 057
Profit/loss for the period	-14 776	-22 725	-50 181
Total non-restricted equity	90 162	41 232	13 816
Total equity	**96 738**	**45 858**	**18 341**
Long-term liabilities			
Other long-term liabilities	0	42 875	28 583
Total long-term liabilities	0	42 875	28 583
Current liabilities			
Accounts payable	7 071	5 643	6 883
Current loan liabilities	0	4 991	19 292
Other liabilities	924	1 024	692
Accrued expenses and deferred income	5 280	4 744	7 842
Total current liabilities	13 276	16 403	34 709
Total liabilities	**13 276**	**59 278**	**63 293**
TOTAL EQUITY AND LIABILITIES	**110 014**	**105 136**	**81 634**

STATEMENT OF CHANGES IN EQUITY FOR THE PARENT COMPANY

Amounts in TSEK	2026 Apr-Jun	2025 Apr - Jun	2026 Jan - Jun	2025 Jan - Jun	2025 Jan - Dec
Total equity at the beginning of the period	**23 645**	**58 356**	**18 341**	**68 641**	**68 641**
Share capital	-10 192	1	-10 192	1	1
Share premium reserve	0	-1	0	-1	-1
Profit or loss brought forward	10 496	0	10 496	0	0
Total comprehensive income for the period	-10 415	-12 441	-14 775	-22 725	-50 181
Rights issue	83 205	38	95 846	38	38
Transaction cost	0	-95	-6 278	-95	-157
Aquisition cost	0	0	3 300	0	0
Total equity at the end of the period	**96 738**	**45 859**	**93 438**	**45 859**	**18 341**

CASH FLOW STATEMENT FOR THE PARENT COMPANY

Amounts in TSEK	2026 Apr-Jun	2025 Apr - Jun	2025 Jan - Jun	2025 Jan - Jun	2025 Jan - Dec
Operating activities					
Operating profit/loss	-10 327	-10 913	-18 734	-20 299	-45 755
Adjustment for items not affecting cash flow	1 218	2 286	2 534	5 137	7 836
Valuation of current assets	0	0	0	-2 409	-2 409
Interest received	13	-19	23	104	197
Interest paid	-41	-997	-1 118	-1 993	-3 917
Dividends	0	0	5 000	0	0
Cash flow from operating activities before changes in working capital	**-9 137**	**-9 642**	**-12 296**	**-19 460**	**-44 048**
Cash flow from changes in working capital					
Increase (-) / decrease (+) of inventories	-13 462	-54	-21 691	4 056	5 021
Increase (-) / decrease (+) of operating receivables	7 020	7 848	6 643	478	-1 430
Increase (+) / decrease (-) of operating liabilities	-11 751	408	-1 837	-6 570	-2 565
Cash flow from operating activities	**-27 329**	**-1 440**	**-29 181**	**-21 495**	**-43 021**
Investing activities					
Investments in tangible assets	0	0	0	0	-999
Acquisition of subsidiary	-304	0	-3 788	0	0
Cash flow from investing activities	**-304**	**0**	**-3 788**	**0**	**-999**
Financing activities					
Rights issue for the year	83 205	38	87 265	38	38
Transaction cost	0	-95	-2 978	-95	-157
New loans	0	0	15 000	0	0
Amortization of financial loans	-62 875	39	-62 875	39	48
Cash flow from financing activities	**20 330**	**-18**	**36 412**	**-18**	-71
Total cash flow for actual period	**-7 303**	**-1 458**	**3 443**	**-21 513**	**-44 091**
Cash and cash equivalents, opening balance	14 316	28 171	3 454	48 252	48 252
Exchange rate difference in cash and cash equivalents	-61	-512	55	-538	-706
Cash and cash equivalents, closing balance	**6 952**	**26 201**	**6 952**	**26 201**	**3 454**

NANOLOGICA

Nanologica AB (publ)
Box 2073
SE-151 02 Södertälje, Sweden
Ph: +46-8-410 749 49
info@nanologica.com
www.nanologica.com